ERBB2 and neoplasm: Moreover, abundant examples from experimental models and clinical trials suggest that HER-2 can be immunogenic and generate antibodies, CTL- and helper T-cell-specific responses in individuals with HER-2-overexpressing tumours (Fisk et al, 1995; Kono et al, 1998).